The Site-less Trial Commences with the Heartline Study Powered by Apple, Evidation Health & Janssen (J&J)
Johnson & Johnson’s Janssen Pharmaceutical unit inked a partnership with Apple to leverage the iPhone and FDA-complaint apps for a […]
Janssen & PRA Design First Truly 100% Mobile Virtual Trial
Janssen Pharmaceuticals and clinical research organization (CRO) PRA Health Sciences recently came together and jointly designed what is purported to […]
Johnson & Johnson (Janssen) Buys MIT Spinoff to Transform Bladder Cancer Treatment
Bladder cancer impact about 1.6 million globally with 550,000 new cases and 200,000 deaths annually. Europeans and North Americans face […]
Bermekimab Goes to Janssen for up to $1.35b in Deal that Could Shake up Future Hidradenitis Suppurativa & Atopic Dermatitis Market
XBiotech’s Bermekimab, a promising experimental drug generating significant interest with Hidradenitis Suppurativa patients in the TrialSite News network, has been […]
Janssen Presents Positive Data from DISCOVER-1 and -2 Studies of Tremfya for Psoriatic Arthritis
Janssen presented positive data from the DISCOVER-1 and DISCOVER-2 Phase 3 studies, which were designed to evaluate the efficacy and […]
FDA Grants Breakthrough Designation to Janssen’s Niraparib for the Treatment of Metastatic Castration-Resistant Prostate Cancer
Janssen announced the FDA has granted Breakthrough Therapy Designation for niraparib for the treatment of patients with BRCA1/2 gene-mutated metastatic […]
Janssen Submits sNDA for Spravato CIII Nasal Spray for the Rapid Reduction of Depressive Symptoms in Adults with Major Depressive Disorder and Active Suicidal Ideation with Intent
Janssen announced the submission of a supplemental New Drug Application (sNDA) to the U.S. FDA seeking a new indication for […]
Janssen’s Invokana Receives FDA Approval to Slow Diabetic Kidney Disease
Janssen announced the U.S. FDA approved a new indication for Invokana (canagliflozin) to reduce the risk of end-stage kidney disease […]
Janssen’s Phase 3 OPTIMUM Study Meets Endpoint of Ponesimod Superiority Versus Aubagio in Adults With Relapsing Multiple Sclerosis
Janssen presented results from the Phase 3 OPTIMUM study for ponesimod, showing superior efficacy on the primary endpoint and most […]
Janssen Launches the Global ‘Mosaico’ HIV Vaccine Efficacy Clinical Trial in Partnership with NIAID and Others
The National Institutes of Health (NIH) and partners today announced plans to conduct a Phase 3 HIV vaccine efficacy trial […]
